I recently came across a stock in the US stock market: $CGEM .

The current price is around 12, and I personally see it reaching the 25 range (estimated in 1 year).
It is a clinical-stage biotech company, and from the chart, the momentum looks very strong.
But the problem is also very clear—the core risk is not in the K-line, but in whether the drug can be successfully developed.
If the clinical data falls short of expectations, it could be cut in half immediately.
So, this type of stock can only be traded as a trend trade.